Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration

Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration

Detalles Bibliográficos
Main Authors:	Chakravarthy, U, Harding, S, Rogers, C, Downes, S, Lotery, A, Wordsworth, S, Reeves, B
Formato:	Journal article
Publicado:	2012

Títulos similares

Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.
por: Chakravarthy, U, et al.
Publicado: (2012)

Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial
por: Chakravarthy, U, et al.
Publicado: (2012)

Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial.
por: Dakin, H, et al.
Publicado: (2014)

Quality of fixation in eyes with neovascular age-related macular degeneration treated with ranibizumab.
por: Sivaprasad, S, et al.
Publicado: (2011)

Treat-And-extend bevacizumab for neovascular age-related macular degeneration: The importance of baseline characteristics
por: Rush, R, et al.
Publicado: (2014)

Pharmacogenetic Associations with Vascular Endothelial Growth Factor Inhibition in Participants with Neovascular Age-Related Macular Degeneration in the IVAN Study
por: Lotery, A, et al.
Publicado: (2013)

Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age-related macular degeneration in the ivan study
por: Lotery, A, et al.
Publicado: (2013)

Long-Term intraocular pressure changes in patients with neovascular age-related macular degeneration treated with Ranibizumab
por: Menke, Marcel N., et al.
Publicado: (2013)

Comparing fixation location and stability in patients with neovascular age-related macular degeneration treated with or without Ranibizumab.
por: Pearce, E, et al.
Publicado: (2011)

Which visual acuity measurements define high-quality care for patients with neovascular age-related macular degeneration treated with ranibizumab?
por: Ross, A, et al.
Publicado: (2013)

Radiotherapy for neovascular age-related macular degeneration.
por: Evans, JR, et al.
Publicado: (2010)

Colour photographs for screening in neovascular age-related macular degeneration: are they necessary?
por: Hibbs, S, et al.
Publicado: (2011)

Evolving European guidance on the medical management of neovascular age related macular degeneration.
por: Chakravarthy, U, et al.
Publicado: (2006)

Optical coherence tomography in neovascular age-related macular degeneration
por: Chong, V
Publicado: (2012)

Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data
por: Spaide, Richard F., et al.
Publicado: (2021)

Serum autoantibody biomarkers for age-related macular degeneration and possible regulators of neovascularization.
por: Morohoshi, K, et al.
Publicado: (2012)

The design and implementation of a study to investigate the effectiveness of community vs hospital eye service follow-up for patients with neovascular age-related macular degeneration with quiescent disease
por: Taylor, J, et al.
Publicado: (2015)

A pilot study on the combination treatment of reduced-fluence photodynamic therapy, intravitreal ranibizumab, intravitreal dexamethasone and oral minocycline for neovascular age-related macular degeneration.
por: Sivaprasad, S, et al.
Publicado: (2011)

Prevalence and genetic analyses of selected age-related macular degeneration-related polymorphisms and their responses to intravitreal ranibizumab
por: Mohamad, Nur Afiqah
Publicado: (2018)

The cost-effectiveness of community versus hospital eye service follow-up for patients with quiescent treated age-related macular degeneration alongside the ECHoES randomised trial
por: Violato, M, et al.
Publicado: (2016)

Deliberations of an International Panel of Experts on OCT Angiography Nomenclature of Neovascular Age-Related Macular Degeneration
por: Mendonça, Luísa SM, et al.
Publicado: (2022)

Early detection of neovascular age-related macular degeneration: an economic evaluation based on data from the EDNA study
por: Hernandez, R, et al.
Publicado: (2021)

Quantitative Optical Coherence Tomography Angiography of Choroidal Neovascularization in Age-Related Macular Degeneration
por: Jia, Yali, et al.
Publicado: (2015)

Artificial intelligence for morphology-based function prediction in neovascular age-related macular degeneration
por: von der Emde, L, et al.
Publicado: (2019)

Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA).
por: Schmidt-Erfurth, U, et al.
Publicado: (2014)

The Effectiveness, cost-effectiveness and acceptability of Community versus Hospital Eye Service follow-up for patients with neovascular age-related macular degeneration with quiescent disease (ECHoES): a virtual randomised balanced incomplete block trial.
por: Reeves, B, et al.
Publicado: (2016)

Stereotactic radiotherapy for neovascular age-related macular degeneration (STAR): a pivotal, randomised, double-masked, sham-controlled device trial
por: Jackson, TL, et al.
Publicado: (2024)

Autologous transplantation of the retinal pigment epithelium and choroid in the treatment of neovascular age-related macular degeneration.
por: Maclaren, R, et al.
Publicado: (2007)

Second eye of patients with unilateral neovascular age-related macular degeneration: Caucasians vs Chinese.
por: Sivaprasad, S, et al.
Publicado: (2006)

Deficient RPE mitochondrial energetics leads to subretinal fibrosis in age-related neovascular macular degeneration
por: Ma, X, et al.
Publicado: (2024)

Association of HTRA1 and ARMS2 gene polymorphisms with response to intravitreal ranibizumab among neovascular age-related macular degenerative subjects
por: Mohamad, Nur Afiqah, et al.
Publicado: (2019)

Long-term results of submacular surgery combined with macular translocation of the retinal pigment epithelium in neovascular age-related macular degeneration.
por: Maclaren, R, et al.
Publicado: (2005)

rs10737680 polymorphism in complement factor H and neovascular age-related macular degeneration in Yogyakarta, Indonesia
por: Sigalingging, Talenta, et al.
Publicado: (2022)

Association of the HtrA1 rs11200638 Polymorphism with Neovascular Age-Related Macular Degeneration in Indonesia
por: Supanji, Supanji, et al.
Publicado: (2021)

Type 1 choroidal neovascularization is associated with reduced localized progression of atrophy in age-related macular degeneration
por: Pfau, M, et al.
Publicado: (2019)

Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.
por: Schmidt-Erfurth, U, et al.
Publicado: (2014)

Intravitreal aflibercept injection for neovascular age-related macular degeneration: Ninety-six-week results of the VIEW studies
por: Schmidt-Erfurth, U, et al.
Publicado: (2014)

Positive response to intravitreal ranibizumab in the treatment of choroidal neovascularization secondary to punctate inner choroidopathy.
por: Menezo, V, et al.
Publicado: (2010)

Inner retinal layer change in glaucoma patients receiving anti-VEGF for neovascular age related macular degeneration.
por: Saleh, Rafidah, et al.
Publicado: (2017)

Should avastin be used to treat age-related macular degeneration in the NHS?--No.
por: Chong, N
Publicado: (2009)